摘要
目的探究不同疗程阿奇霉素治疗稳定期慢性阻塞性肺疾病(COPD)的疗效及安全性。方法选取2019年6月至2021年6月于武汉市汉口医院因COPD急性发作经治疗后转为稳定期的210例COPD患者作为研究对象,按照用药疗程的不同分为A组、B组与C组,每组70例。3组均给予阿奇霉素治疗,A组用药3个月,B组用药6个月,C组用药9个月,比较3组治疗前后第1秒用力呼气容积(FEV_(1))、FEV_(1)占用力肺活量比值(FEV_(1)/FVC)、FEV_(1)占预计值百分比(FEV_(1)%)、6 min步行试验距离(6MWT)、急性加重次数及治疗期间不良反应发生率。结果治疗后,3组FEV_(1)均大于治疗前,FEV_(1)/FVC、FEV_(1)%均高于治疗前,且B组、C组FEV_(1)均大于A组,FEV_(1)/FVC、FEV_(1)%均高于A组,C组FEV_(1)大于B组,FEV_(1)/FVC、FEV_(1)%均高于B组,差异有统计学意义(P<0.05)。治疗后,3组6MWT均大于治疗前,急性加重次数均少于治疗前,且B组、C组6MWT均大于A组,急性加重次数均少于A组,C组急性加重次数少于B组,差异有统计学意义(P<0.05),B组与C组6MWT比较差异无统计学意义。3组不良反应发生率比较差异无统计学意义。结论不同疗程阿奇霉素治疗稳定期COPD患者疗效均较佳,均可改善患者肺功能及活动能力,减少急性加重次数,但用药9个月的效果最好,不良反应发生率低,值得临床推广应用。
Objective To explore Efficacy and safety of different courses of azithromycin in the treatment of stable chronic obstructive pulmo-nary disease(COPD).Methods A total of 210 COPD patients who transitioned from acute exacerbation to stable phase after treatment in Hankou Hospital in Wuhan from June 2019 to June 2021 were selected as the study subjects,and they were divided into the group A,group B,and group C according to different treatment durations,with 70 cases in each group.All three groups received azithromycin treatment,group A was treated for 3 months,group B was treated for 6 months,and group C was treated for 9 months,the forced expiratory volume in one second(FEV_(1)),the ratio of FEV_(1)to forced vital capacity(FEV_(1)/FVC),percentage of FEV_(1)to predicted values(FEV_(1)%),6-minute walk test(6 MWT)distance,and frequency of acute exacerbations before and after treatment and the incidence of adverse reactions during treatment were compared among the three groups.Results After treatment,FEV_(1)of three groups was greater than before treatment,FEV_(1)/FVC and FEV_(1)%were higher than before treatment,and FEV_(1)in the group B and the group C were greater than the group A,FEV_(1)/FVC and FEV_(1)%were higher than the group A,FEV_(1)/FVC and FEV_(1)%in the group C was greater than the group B,FEV_(1)/FVC and FEV_(1)%were higher than the group B,the differences were statistically significant(P<0.05).After treatment,the 6 MWT of the three groups were greater than that before treatment,and the frequency of acute exacerbations were less than that before treatment,and the 6 MWT in the group B and the group C were greater than that in the group A,the frequency of acute exacerbations was less than that in the group A,and the frequency of acute exacerbations in the group C was less than that in the group B,and the differences were statistically significant(P<0.05);there was no statistically significant difference in the 6 MWT between the group B and the group C.There was no significant difference in the incidence of adverse reactions among the three groups.Conclusion Different courses of azithromycin in the treatment of stable COPD patients have good curative effect,can improve the lung function and mobility of patients,reduce the number of acute exacerbations,but the effect of 9 months of treatment is the best,the incidence of adverse reactions is low,worthy of clinical promotion and application.
作者
李晓端
操银针
任品宽
LI Xiaoduan;CAO Yinzhen;REN Pinkuan(Department of Pharmacy,Hankou HospitalWuhan,Hubei,430012,China)
出处
《当代医学》
2023年第25期166-169,共4页
Contemporary Medicine
关键词
慢性阻塞性肺疾病
稳定期
阿奇霉素
疗程
肺功能
并发症
Chronic obstructive pulmonary disease
Stable phase
Azithromycin
Treatment durations
Pulmonary function
Complications
